Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Pediatr.

Sec. Obstetric and Pediatric Pharmacology

Volume 13 - 2025 | doi: 10.3389/fped.2025.1694368

Drug review: mTOR-inhibitortherapy in fetal cardiacrhabdomyoma—a tightrope walk

Provisionally accepted
Nadine  MuschelNadine Muschel1Michaela  HöckMichaela Höck1Elke  GriesmaierElke Griesmaier1Samira  Abdel-AzimSamira Abdel-Azim1Elisabeth  RalserElisabeth Ralser1Christina  SchreinerChristina Schreiner1Elisabeth  SchermerElisabeth Schermer1Ursula  Kiechl-KohlendorferUrsula Kiechl-Kohlendorfer1Irene  Mutz-DehbalaieIrene Mutz-Dehbalaie1Miriam  MichelMiriam Michel2*
  • 1Medizinische Universitat Innsbruck, Innsbruck, Austria
  • 2Innsbruck Medical University, Innsbruck, Austria

The final, formatted version of the article will be published soon.

Keywords: adverse effects, Fetal cardiac tumor, Rhabdomyoma, Sirolimus, re-entry tachycardia

Received: 28 Aug 2025; Accepted: 29 Aug 2025.

Copyright: © 2025 Muschel, Höck, Griesmaier, Abdel-Azim, Ralser, Schreiner, Schermer, Kiechl-Kohlendorfer, Mutz-Dehbalaie and Michel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Miriam Michel, Innsbruck Medical University, Innsbruck, Austria

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.